For NEW Patient Copay Assistance information, please click on this link
Teva’s Shared Solutions® is committed to helping your patients find affordable access to AJOVY
Patient Services PortalThe support team at CoverMyMeds® can help resolve or automatically initiate PA requests
CoverMyMeds®Get your patients started on AJOVY. Begin here
AJOVY was evaluated in three phase 3, 12-week, randomized, double-blind, placebo-controlled,
parallel-group trials, and a long-term extension.
AJOVY was evaluated in HALO—two phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group trials.1,2
As an extension of the HALO trials, AJOVY was further studied in the Long-Term Extension study—a 12-month, multicenter, randomized, double-blind, parallel-group study evaluating monthly and quarterly dosing.2
As the primary purpose of the study was the collection of long-term safety data for patients treated
with AJOVY, the study was not placebo controlled.2
AJOVY was also evaluated in FOCUS, a phase 3b, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, evaluating efficacy and safety of quarterly and monthly treatment with
AJOVY, compared to placebo in patients with chronic or episodic migraine who had experienced inadequate response to 2–4 classes of prior preventive treatments.3
Teva’s Shared Solutions® is committed to helping your patients find affordable access to AJOVY
Patient Services PortalThe support team at CoverMyMeds® can help resolve or automatically initiate PA requests
CoverMyMeds®